Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...

Combination treatment with cabozantinib and atezolizumab ... Following prostatectomy in patients with recurrent prostate cancer, researchers analyzed post–salvage radiotherapy prostate-specific ...

NUBEQA is indicated in the U.S. for the treatment of adult patients with mHSPC in combination with docetaxel and for the treatment ... 11:25 AM – 12:45 PM PST Darolutamide monotherapy in patients with ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

Men with intermediate-risk prostate cancer and high PSA levels before HIFU treatment had a greater risk of both overall recurrence and treatment failure. Men with intermediate-risk prostate cancer and ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Dec. 3, 2024 — A special protein can play a key role in the fight against certain types of prostate cancer. Until now, treatments have involved blocking the protein in question that builds a so ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure. Patients with HRR-deficient metastatic ...

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...